- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03406611
Pegtibatinase comme thérapie enzymatique pour les patients atteints d'homocystinurie causée par un déficit en cystathionine bêta-synthase (COMPOSE)
Une étude de phase 1/2 en double aveugle, randomisée, contrôlée par placebo pour évaluer l'innocuité, la tolérance, la pharmacocinétique, la pharmacodynamique et les effets sur les résultats cliniques de la pegtibatinase (TVT-058), administrée par voie sous-cutanée chez des patients atteints d'homocystinurie déficiente en cystathionine bêta-synthase (COMPOSER)
L'homocystinurie causée par un déficit en cystathionine bêta-synthase (CBS) est une maladie métabolique autosomique récessive rare caractérisée par un excès d'homocystéine (Hcy) dans le plasma, les tissus et l'urine. Elle est due à une activité réduite ou absente de l'enzyme CBS et est également connue sous le nom d'homocystinurie classique. Les symptômes associés à l'homocystinurie varient en gravité et en temps d'apparition selon les patients. Certaines personnes touchées peuvent présenter des signes bénins de la maladie; d'autres peuvent avoir une atteinte multisystémique, y compris des complications potentiellement mortelles. L'homocystinurie peut affecter de nombreux systèmes d'organes différents du corps; les quatre plus couramment impliqués sont les yeux, le système nerveux central, le squelette et le système vasculaire.
Les approches actuelles du traitement des patients atteints d'homocystinurie comprennent un régime alimentaire très restrictif et l'utilisation de compléments alimentaires. L'observance à vie de ce régime est médiocre. La pegtibatinase (TVT-058) représente une nouvelle approche thérapeutique qui intègre l'utilisation d'une version modifiée de l'enzyme CBS humaine native (hCBS). L'objectif du traitement est d'introduire l'enzyme CBS dans la circulation, ce qui entraîne une réduction des taux d'Hcy et une augmentation des taux de cystathionine (Cth) et de cystéine (Cys).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Primary Objective - Cohorts 1-6
Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).
Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.
Secondary Objectives - Cohorts 1-6
Researchers also want to learn about:
- What are the levels of pegtibatinase in the body after single and repeated doses?
- How does pegtibatinase affect levels of certain substances that are produced when the body breaks down and creates homocysteine?
- What are the effects of pegtibatinase on the eyes, bones, mental health, and cognitive function? Researchers will use blood tests, physical examinations, and questionnaires to answer these questions.
Cohort 7 Objectives
Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.
Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.
Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.
Researchers are performing this part of the study with Group 7 because they also want to learn about:
- What are the levels of pegtibatinase in the pediatric participant's body after single and repeated doses?
- How does pegtibatinase affect levels of total homocysteine and methionine in the pediatric participant's body? Researchers will use blood tests to answer these questions.
Study Population and Treatments
This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.
Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.
Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.
Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.
- Group 1: 0.33 mg/kg pegtibatinase or placebo 1 time a week.
- Group 2: 0.66 mg/kg pegtibatinase or placebo 1 time a week.
- Group 3: 1.0 mg/kg pegtibatinase or placebo 1 time a week.
- Group 4: 1.0 mg/kg pegtibatinase or placebo 2 times a week.
- Group 5: 1.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 6: 2.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 7:
- Part A: 1.0 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part B: 1.5 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part C: 2.5 mg/kg pegtibatinase 2 times a week for 4 weeks.
Study Duration and Visits
Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.
Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.
If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events
Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.
Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Travere Call Center
- Numéro de téléphone: 1-877-659-5518
- E-mail: medinfo@travere.com
Lieux d'étude
-
-
-
Paris, France, 75015
- Pas encore de recrutement
- Hospital Necker-Enfants Malades, Neurologie Pediatrique
-
-
-
-
-
Doha, Qatar
- Pas encore de recrutement
- Sidra Medicine
-
-
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Complété
- Travere Investigational Site
-
-
Florida
-
Miami, Florida, États-Unis, 33136
- Complété
- Travere Investigational Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Pas encore de recrutement
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Complété
- Travere Investigational Site
-
-
Maine
-
Portland, Maine, États-Unis, 04102
- Complété
- Travere Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Complété
- Travere Investigational Site
-
-
New York
-
New York, New York, États-Unis, 10029
- Pas encore de recrutement
- The Mount Sinai Hospital
-
New York, New York, États-Unis, 10029
- Complété
- Travere Investigational Site
-
-
North Carolina
-
Morrisville, North Carolina, États-Unis, 27560
- Recrutement
- Science 37 - Virtual Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Complété
- Travere Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
La description
Critère d'intégration:
- Diagnostic confirmé d'homocystinurie basé sur la confirmation génétique et tHcy plasmatique ≥ 50 micromoles et documentation du niveau précédent de tHcy ≥ 80 micromoles
- Volonté et capable de fournir un consentement éclairé écrit et signé et de se conformer à toutes les procédures liées à l'étude.
- Les sujets nés biologiquement en tant que femmes en âge de procréer doivent avoir un test de grossesse négatif lors du dépistage et être disposés à subir des tests de grossesse supplémentaires au cours de l'étude. Les sujets nés biologiquement en tant qu'hommes qui s'identifient comme des femmes et ne sont pas en âge de procréer ne sont pas tenus de subir des tests de grossesse
- Les sujets sexuellement actifs qui ont le potentiel de procréer ou ceux qui ont des partenaires en âge de procréer doivent être disposés à utiliser des méthodes de contraception acceptables pendant l'étude et pendant 4 semaines après la fin de l'étude
- Disposé à maintenir un régime alimentaire stable sans modifications significatives pendant ses études et à remplir un journal alimentaire quotidien.
Critère d'exclusion:
- Exposition antérieure à la pegtibatinase et/ou participation antérieure à un essai clinique incluant l'administration de pegtibatinase
- Utilisation de tout produit expérimental ou dispositif médical expérimental dans les 30 jours précédant le dépistage ou pendant l'étude
- Utilisation ou utilisation prévue de tout médicament injectable contenant du PEG (autre que les vaccins pegtibatinase ou COVID-19), y compris l'injection de médroxyprogestérone (par exemple, Depo-Provera), dans les 3 mois précédant le dépistage et pendant la participation à l'étude
- Hypersensibilité connue au produit contenant du PEG ou à tout composant de la pegtibatinase
- Un test positif pour les anticorps du VIH, l'antigène de surface de l'hépatite B ou les anticorps de l'hépatite C
- Antécédents de transplantation d'organe, de traitement immunosuppresseur chronique ou de toxicomanie
- Enceinte ou allaitante au dépistage ou prévoyant de devenir enceinte (elle-même ou partenaire) ou d'allaiter à tout moment pendant l'étude
- Maladie ou affection concomitante ou chirurgie majeure planifiée qui interférerait avec la participation à l'étude ou la sécurité de l'avis de l'investigateur.
- Toute condition qui, de l'avis de l'investigateur, expose le sujet à un risque élevé de mauvaise observance du traitement ou de ne pas terminer l'étude
- Chirurgie majeure prévue pendant la période d'étude
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Pegtibatinase (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Solution stérile de pegtibatinase pour injection sous-cutanée
Autres noms:
|
|
Comparateur placebo: Placebo (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Solution saline normale pour injection sous-cutanée
|
|
Expérimental: Pegtibatinase (Cohort 7)
Pediatric Open-label Treatment Cohort (≥5 to <12 years)
|
Solution stérile de pegtibatinase pour injection sous-cutanée
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of AEs
Délai: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Incidence of AEs (by type, severity and relationship to study drug)
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-pegtibatinase antibodies
Délai: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-PEG antibodies
Délai: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Incidence of hypermethioninemia (Cohort 7 only)
Délai: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold.
Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
Incidence of hypomethioninemia (Cohort 7 only)
Délai: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold.
Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
Délai: First dose through End of Treatment (up to Week 32)
|
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
|
First dose through End of Treatment (up to Week 32)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in pegtibatinase levels
Délai: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - tHcy
Délai: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in total homocysteine levels in micromoles
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Changes in total cysteine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Changes in methionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Changes in cystathionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Changes in phenylalanine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]).
Assessment of presence and severity of findings.
|
Through double-blind study completion, approximately 10 months per patient
|
|
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
|
Through double-blind study completion, approximately 10 months per patient
|
|
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
Délai: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Michael Imperiale, MD, Travere Therapeutics, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Métabolisme, erreurs innées
- Maladies génétiques, innées
- Maladies métaboliques
- Maladies du tissu conjonctif
- Maladies cérébrales, métaboliques, innées
- Maladies cérébrales métaboliques
- Métabolisme des acides aminés, erreurs innées
- Hyperhomocystéinémie
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies nutritionnelles et métaboliques
- Maladies de la peau et du tissu conjonctif
- Homocystinurie
Autres numéros d'identification d'étude
- CBS-HCY-CT-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .